Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- PMID: 21248752
- PMCID: PMC3030920
- DOI: 10.1038/nature09639
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Erratum in
- Nature. 2012 Apr 5;484(7392):130
Abstract
The genetics of renal cancer is dominated by inactivation of the VHL tumour suppressor gene in clear cell carcinoma (ccRCC), the commonest histological subtype. A recent large-scale screen of ∼3,500 genes by PCR-based exon re-sequencing identified several new cancer genes in ccRCC including UTX (also known as KDM6A), JARID1C (also known as KDM5C) and SETD2 (ref. 2). These genes encode enzymes that demethylate (UTX, JARID1C) or methylate (SETD2) key lysine residues of histone H3. Modification of the methylation state of these lysine residues of histone H3 regulates chromatin structure and is implicated in transcriptional control. However, together these mutations are present in fewer than 15% of ccRCC, suggesting the existence of additional, currently unidentified cancer genes. Here, we have sequenced the protein coding exome in a series of primary ccRCC and report the identification of the SWI/SNF chromatin remodelling complex gene PBRM1 (ref. 4) as a second major ccRCC cancer gene, with truncating mutations in 41% (92/227) of cases. These data further elucidate the somatic genetic architecture of ccRCC and emphasize the marked contribution of aberrant chromatin biology.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030920/bin/ukmss-33194-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030920/bin/ukmss-33194-f0002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030920/bin/ukmss-33194-f0003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030920/bin/ukmss-33194-f0004.gif)
Similar articles
-
Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.Neoplasia. 2019 Feb;21(2):247-256. doi: 10.1016/j.neo.2018.12.006. Epub 2019 Jan 16. Neoplasia. 2019. PMID: 30660076 Free PMC article.
-
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
-
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.Cancer Genet. 2015 May;208(5):206-14. doi: 10.1016/j.cancergen.2015.02.008. Epub 2015 Feb 20. Cancer Genet. 2015. PMID: 25873528 Free PMC article. Review.
-
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.Genes Chromosomes Cancer. 2014 Jan;53(1):38-51. doi: 10.1002/gcc.22116. Epub 2013 Oct 29. Genes Chromosomes Cancer. 2014. PMID: 24166983
-
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.Epigenetics. 2013 May;8(5):486-93. doi: 10.4161/epi.24552. Epub 2013 May 1. Epigenetics. 2013. PMID: 23644518 Free PMC article.
Cited by
-
A latent variable model for evaluating mutual exclusivity and co-occurrence between driver mutations in cancer.bioRxiv [Preprint]. 2024 Apr 27:2024.04.24.590995. doi: 10.1101/2024.04.24.590995. bioRxiv. 2024. PMID: 38712136 Free PMC article. Preprint.
-
Fast and accurate variant identification tool for sequencing-based studies.BMC Biol. 2024 Apr 22;22(1):90. doi: 10.1186/s12915-024-01891-4. BMC Biol. 2024. PMID: 38644496 Free PMC article.
-
Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.Cancer Immunol Immunother. 2024 Apr 12;73(5):95. doi: 10.1007/s00262-024-03681-x. Cancer Immunol Immunother. 2024. PMID: 38607586 Free PMC article.
-
The Killer's Web: Interconnection between Inflammation, Epigenetics and Nutrition in Cancer.Int J Mol Sci. 2024 Feb 27;25(5):2750. doi: 10.3390/ijms25052750. Int J Mol Sci. 2024. PMID: 38473997 Free PMC article. Review.
-
PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.Front Oncol. 2024 Feb 2;14:1343004. doi: 10.3389/fonc.2024.1343004. eCollection 2024. Front Oncol. 2024. PMID: 38371625 Free PMC article.
References
-
- Kouzarides T. Chromatin Modifications and Their Function. Cell. 2007;128:693–705. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous